Right after reporting encouraging data with its Dravet syndrome gene therapy, Encoded Therapeutics has raised an impressive ...

AbbVie's Qulipta has become the first oral CGRP inhibitor to show efficacy in a phase 3 study involving women with menstrual ...

The National Commission into the Regulation of AI in Healthcare has delivered its keenly anticipated report, which gives ...

Jiangsu Hengrui Pharma's oral thrombopoietin (TPO) receptor agonist hetrombopag has been approved in China to treat low ...

Gilead's twice-yearly injectable for pre-exposure prophylaxis (PrEP) of HIV, lenacapavir, will not be routinely funded by the ...

The pivotal QUINTESSENTIAL trial of the potentially first-in-class CAR-T showed a "statistically significant and clinically ...

An NHS trust in the UK has become the first site in Europe to offer Roche's experimental drug trontinemab to patients ...

Amgen's fast-growing cancer immunotherapy Imdelltra could move into the first-line setting in small cell lung cancer (SCLC), ...

At present, the only FDA-approved oral therapies for HAE are BioCryst's Orladeyo (berotralstat) and KalVista Pharma's Ekterly ...

Novo Nordisk has opted to discontinue two late-stage trials of IL-6 inhibitor ziltivekimab in heart failure, after an interim ...

Novartis' oral BTK inhibitor remibrutinib has shown efficacy in a pair of phase 3 trials in relapsing multiple sclerosis (RMS ...

Omnideployment is not about multiplying touchpoints or increasing the volume of communications. It is the precise ...